MicroRNA 4669 (MIR4669)

MicroRNA 4669 (MIR4669, also known as hsa-mir-4669) is a short non-coding RNA molecule in humans that belongs to the class of microRNAs, typically 20–24 nucleotides in length[1]. Like other miRNAs, it functions by regulating gene expression post-transcriptionally, mainly through binding to complementary sequences in messenger RNA (mRNA) molecules, leading to inhibition of translation or mRNA degradation[1][3][5]. MIR4669 has been associated in some studies with vascular pathologies: polymorphisms in its precursor region (such as SNP rs35196866) may affect its maturation and impact risk or severity of ischemic stroke, and its expression level is reportedly lower in patients with in-stent restenosis[2]. Predicted biological targets include fibroblast growth factor receptor-like 1 (FGFRL1) and neural cell adhesion molecule 1 (NCAM1), implicating it in vascular integrity and neurological disease processes[2]. However, there are no approved drugs targeting MIR4669; its clinical use is currently limited to a potential research biomarker for vascular disease risk stratification[2].

Other names

hsa-mir-4669MIR4669

Not applicable for drugs (no direct drug-target relationship established) - For general function: Binds target mRNAs in a sequence-specific manner, usually leads to translational repression or mRNA degradation